FluxMPS™ CMRL 1066 Medium: 1X Liquid

FluxMPS™ CMRL 1066 Medium: 1X Liquid

FluxMPS™ CMRL 1066 Medium: 1X Liquid is an MPS-grade, ultra-filtered cell culture medium engineered for organ-on-a-chip (OoC), tissue-on-a-chip (ToC), and microphysiological system (MPS) applications. Processed through a proprietary Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2), it delivers approximately 5× cleaner media than conventional 0.22 µm-filtered formulations by particulate count — making it microchannel-safe from day one.

• Quadruple-stage nano-filtration: 0.1 µm (Pre-filtration I & III) + 0.04 µm (Pre-filtration II & Final Polish)
• Endotoxin: less than 0.05 EU/mL (USP <85> BET verified)
• CMRL 1066 Medium: 1X Liquid base formulation; pH 7.4 (USP <791>)
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm), USP <85>
• ISO Class 5 aseptic fill & finish; ISO 13485:2016 QMS manufacturing
• Mycoplasma-controlled via sub-0.1 µm final filter stage
• Custom formulations available — pH, glucose, salts, HEPES, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered media carry mycoplasma-sized particulates (0.1–0.3 µm), subvisible debris, and endotoxin spikes that accumulate inside microchannels — corrupting biosensor readings, triggering inflammation in primary cultures, and shortening device lifetimes. FluxMPS™ eliminates these failure modes at the source.

Quadruple-stage filtration system

FluxMPS™ CMRL 1066 Medium: 1X Liquid is the only ready-to-use formulation processed through a four-stage serial filtration sequence that reaches 0.04 µm — eliminating mycoplasma, subvisible particles, and bioburden that 0.22 µm filtration cannot address.

1. 1

   0.1 µm Pre-filtration I

   Removes large particulates and aggregates; protects downstream filter geometry and extends filter life across microchannel-scale flow paths.

2. 2

   0.04 µm Pre-filtration II

   Fine particulate and bacteria removal; retains mycoplasma (typical diameter 0.1–0.3 µm) — a critical step absent in standard 0.22 µm filtration.

3. 3

   0.1 µm Sterile-filtration I

   Second-pass redundancy for residual contaminants and bioburden; ensures no breakthrough from Stage 1 reaches the final filter.

4. 4

   0.04 µm Sterile-filtration II — Final Polish

   Ultimate polishing step; ISO Class 5 aseptic fill performed in a validated laminar-flow workstation under full GMP-aligned conditions.

Designed for next-generation cell culture platforms

FluxMPS™ CMRL 1066 Medium: 1X Liquid is validated for use across organ-on-a-chip, metabolic research, live-cell imaging, and primary cell models where particulate contamination and endotoxin variation are unacceptable.

Automated Bioreactors & Robotics

An optional 0.01 µm (10 nm) ultra-filtered variant is available for automated bioreactor and robotic perfusion systems requiring the ultimate particulate exclusion.

• Total Particulate Exclusion: 10 nm filtration for nanoscale valve and sensor protection
• Valve & Sensor Protection: prevents particulate-induced blockage in precision fluidic systems
• Extended Perfusion Stability: maintains flow rate consistency across multi-week automated runs

Inquiry Required: The 0.01 µm grade is available by special order. Contact support@diagnocine.com to request this variant.

Lot-release quality parameters

Every production lot of FluxMPS™ CMRL 1066 Medium: 1X Liquid undergoes the complete quality-release battery listed below before shipment.

Full composition (mg/L)

Complete formulation with CAS numbers. All ingredient names and mg/L values are reproduced from the manufacturer specification. Custom compositions available on request.

ISO 13485:2016 manufacturing & compliance

FluxMPS™ CMRL 1066 Medium: 1X Liquid is manufactured under a full ISO 13485:2016 quality management system, with final packaging, testing, and customization completed at DiagnoCine Precision in Totowa, New Jersey, USA.

How DCP-CMRL1X (FluxMPS™) compares

Side-by-side comparison against conventional 0.22 µm-filtered alternatives of the same base formulation.

Frequently asked questions

Common questions about FluxMPS™ CMRL 1066 Medium: 1X Liquid and MPS-grade cell culture media.

Supporting literature

Peer-reviewed publications supporting the scientific rationale for MPS-grade ultra-filtered media and microfluidic cell culture applications.

1. Huh D et al. (2010). Reconstituting organ-level lung functions on a chip. Science, 328(5986), 1662–1668. doi:10.1126/science.1188302
2. Bhatia SN & Ingber DE (2014). Microfluidic organs-on-chips. Nature Biotechnology, 32(8), 760–772. doi:10.1038/nbt.2989
3. Bhattacharya S et al. (2018). Challenges in maintaining cell viability during microfluidic experiments. Electrophoresis, 39(7), 997–1006. doi:10.1002/elps.201700375
4. Warburg O (1956). On the origin of cancer cells. Science, 123(3191), 309–314. doi:10.1126/science.123.3191.309
5. Emmons EV (1965). Detection of mycoplasma in cell cultures using filtration. Proceedings of the Society for Experimental Biology, 118, 1010–1015. doi:10.3181/00379727-118-29988
6. Kim S et al. (2012). Gut-on-a-chip microdevice replicates key functional features of the human intestine. Lab on a Chip, 12(12), 2165–2174. doi:10.1039/c2lc40074j
7. Zhang YS et al. (2017). Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. PNAS, 114(12), E2293–E2302. doi:10.1073/pnas.1612906114
8. Vernetti L et al. (2017). Functional coupling of human microphysiology systems. Scientific Reports, 7, 42296. doi:10.1038/srep42296
9. Schuster B et al. (2020). Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nature Communications, 11, 5271. doi:10.1038/s41467-020-19058-4
10. Zheng F et al. (2021). Organ-on-a-chip systems: microengineering to biomimic living systems. Small, 17(7), 2004175. doi:10.1002/smll.202004175